Inventiva SA

Inventiva is a clinical stage biotechnology research company delivering therapies in the areas of oncology, fibrosis and rare diseases. The most advanced clinical programs (IVA337 for systemic sclerosis in Non-Alcoholic Steato-Hepatitis and IVA336 for Maroteaux-Lamy syndrome-MPS VI) have demonstrated efficacy in relevant in vivo and in vitro models as well as safety in phase I and phase II clinical trials. Using its in-house drug discovery platform, which covers target validation, screening, chemistry, ADME and pharmacology, Co. is developing an internal oncology and fibrosis discovery pipeline with approaches centered on transcription factors, epigenetics targets and nuclear receptors.
  • TickerIVA
  • ISINFR0013233012
  • ExchangeEuronext Paris
  • SectorPharmaceuticals & Biotechnology
  • CountryFrance
Alan Vandenberghe ...
  • Guy Sips
  • Jason Kalamboussis
  • Joachim Vansanten
  • Lenny Van Steenhuyse
  • Michiel Declercq
  • Sandra Cauwenberghs
  • Wido Jongman
  • Wim Hoste

Dynamic Top pick List 2020 - Update

Today we update our Dynamic Top Pick List : • We ADD : Care Property Invest • We KEEP : AB Inbev, Ahold Delhaize, Barco, Basic-Fit, Hal Trust, NN Group, UCB, VGP, WDP, Recticel and Inventiva. Since inception our DTPL is only down 2.4%, which represents an outperformance of 3.6%, 12.2% and 9.3% compared to the AEX, BEL20 and SX5E respectively. In June, our list underperformed all 3 benchmarks by 1.4% on average despite a very solid performance of UCB. The main contributors to this negative performance were : AB Inbev, Basic-Fit and Inventiva

Jason Kalamboussis ...
  • Joachim Vansanten
  • Lenny Van Steenhuyse
  • Sandra Cauwenberghs
  • Wido Jongman

Morning Note: CPINV BB, IVA FP, NN NA

CP Invest: First toe in the water in Spain Inventiva: Crossing the pond: $ 90m US IPO planned NN Group: New Report : Longevity market analysis

Alan Vandenberghe ...
  • Jason Kalamboussis
  • Joachim Vansanten
  • Lenny Van Steenhuyse
  • Ruben Devos
  • Sandra Cauwenberghs
  • Wido Jongman
  • Wim Hoste

Morning Note: AGS BB, ATEB BB, BPOST BB, GREEN BB, IVA FP, RET BB, SEQUA:BB, UMI BB

Ageas: Chinese premiums growth back on track in style Atenor: Sale of last office building Au Fil Des Grands Pres bpost: CEO mentioned in potential market abuse case Greenyard: No surprises for FY19/20, guidance a bit soft Inventiva: Lanifibranor sets the new bar in NASH treatment Retail Estates: Increase of estimates post rent deal Sequana Medical: MOSAIC alfapump study results published Umicore: Issues € 500m convertible bonds Dynamic Top Pick List: Adding Inventiva to the dynamic topic list

Lenny Van Steenhuyse

INVENTIVA : Lanifibranor - above and beyond what’s expected

Inventiva establishes itself as a force to be reckoned with in the NASH field with the NATIVE trial data of panPPAR agonist lanifibranor. Impact on both NASH resolution and fibrosis improvement previously only seen in injectable biologics make lanifibranor a candidate as backbone therapy in NASH.

Bart Cuypers ...
  • Jason Kalamboussis
  • Joachim Vansanten
  • Lenny Van Steenhuyse
  • Michiel Declercq
  • Ruben Devos
  • Sandra Cauwenberghs
  • Wido Jongman

Morning Note: ACKB BB, AED BB, ASRNL NA, CFEB BB, ELI BB, GIMB BB, HAL NA, HOMI BB, IVA FP, MITRA BB, ROU BB, TWEKA NA

Ackermans: 1Q Trading update Aedifica: 3Q19-20 trading update ASR: Weak 1Q, profit warning. Solid Solvency though. CFE: Soft DEME revenue and strongly impacted FY20 Elia Group: Steady as she goes Gimv: FY19/20 Results imply a large premium Hal Trust: 1Q20 Update Home Invest Belgium: 1Q20 Results show signs of improvement Inventiva: € 10m government-backed loan secured Mithra: Estelle NDS filed in Canada. Potential launch mid-21. Roularta: Qualitative trading update TKH Group: Forward EPS lowered by 25-35%, new TP of € 45

ResearchPool Subscriptions

Get the most out of your insights

Get in touch